Pulmonary Regurgitation clinical trials at UCSF

2 in progress, 1 open to eligible people

Pulmonary regurgitation is when the heart's pulmonary valve does not close properly, causing blood to flow backward. UCSF is studying a new heart valve called SAPIEN 3 to see if it is safe and works well for patients. These trials are now open for volunteers.

Showing trials for

  • COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

    open to all eligible people

    This study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3/SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve (THV) Systems in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position with a clinical indication for intervention.

    San Francisco, California and other locations

  • ALTERRA: SAPIEN 3 THV With the Alterra Adaptive Prestent

    Sorry, in progress, not accepting new patients

    To demonstrate the safety and effectiveness of the Edwards Alterra Adaptive Prestent in conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract/pulmonary valve (RVOT/PV) who are indicated for treatment of pulmonary regurgitation (PR). Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

    San Francisco, California and other locations

Last updated: